ArticleAME case reports2025
Testicular teratoma and primary retroperitoneal choriocarcinoma with lung metastasis: a case report.
Article in AME case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Male primary retroperitoneal choriocarcinoma (PRC) is rare with poor prognosis. No literature reports co-occurrence of testicular teratoma and PRC diagnosed after puberty. Case Description: A 23-year-old man presented pain in the right lower abdomen for 11 days without any other symptoms. He claimed he was not a smoker and had no history of any disease. Physical examination found his pain got worse in supine position. Laboratory testing found white blood cell count of 11.0×10 Conclusions: This is the first study that has reported such a rare co-occurrence of male PRC with lung metastasis and testicular mature teratoma diagnosed after puberty. Surgery is the first choice for this case. A thorough evaluation of the retroperitoneal tumor before surgery is critical for the surgeon to pick an appropriate operation program. Immunochemical markers can provide some evidence for the subsequent treatment and prognosis prediction. Very poor prognosis with only 11-month survival time is predicted by both tumors having high percentage of Ki-67 +, the retroperitoneal tumor having vascular and neural invasiveness with lung metastasis, and high malignancy of male PRC at the late stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.